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F.-Ulrich Hartl and Arthur Horwich will share this year’s Lasker Basic Medical Science Award for the
discovery of the cell’s protein-folding machinery, exemplified by cage-like structures that convert
newly synthesized proteins into their biologically active forms. Their fundamental findings reveal
mechanisms that operate in normal physiologic processes and help to explain the problems that
arise in diseases of protein folding.How is it that, even when proteins cannot
fold on their own in vitro, they somehow
fold beautifully in the much more complex
environment of a cell? As with most
breakthrough discoveries in biology, the
answer is remarkably simple: the cell pro-
vides special protein machinery, called
molecular chaperones, that surrounds
the folding protein and removes it from
the rest of the cell.
The surfaces of this remarkable ma-
chinery are very forgiving. They actually
utilize metabolic energy (i.e., ATP hydro-
lysis) to alternate their physical chemistry
between hydrophobic states and hydro-
philic states, which restarts the folding
when it stalls and expels the protein
when folding is completed. In the case
of the heat shock protein 60 (Hsp60), a
molecular chaperone shaped like a test
tube, access to the cavity is highly selec-
tive and limited to only nascent proteins or
those purposely unfolded to repair con-
formational damage. Analogous special-
ized test tube environments, also based
on limited access to the internal cavity of
a ring-based protein structure, enable tar-
geted proteolysis (by proteosomes),
making this strategy a general principle
in cellular biology.
These singular discoveries are cele-
brated in this year’s Lasker Basic Medical
Research Award to F.-Ulrich Hartl and
Arthur Horwich. In collaborative work,
they discovered the fundamental principle
that protein folding in the cell is generally
a facilitated process, and in independent
and often complementary work, they
and their collaborators established thepathway and molecular mechanisms in-
volved in this process. Together, the
discoveries of Hartl and Horwich stand
at the apex of decades of work by many
investigators who helped start and extend
the field of protein folding in the cell.
The pathway of protein folding is utterly
general; it is essentially the same in bac-
teria, fungi, plants, animals, and of course
humans. The full implication of the latter is
that when the pathway is saturated, or its
coupling to the pathway of protein degra-
dation is imperfect, then protein aggre-
gates accumulate in the cell. Depending
on the nature of the protein species
involved, this can result in neurodegener-
ative disease, such as Alzheimer’s,
Huntington’s, Creutzfeld Jacob’s, and
Parkinson’s Diseases, or can affect other
tissues, as in cystic fibrosis.
Freeing Proteins to Fold
The achievements of Hartl and Horwich
must be seen in a historical perspective.
In 1972, Christian Anfinsen received a
Nobel Prize for discovering in the 1950s
that proteins assume their three-dimen-
sional conformations and therefore gain
their catalytic potential, exclusively based
on primary instructions in their intrinsic
amino acid sequence. This insight forged
the link between the genetic code and
protein function, but it emerged from
simple denaturation-renaturation experi-
ments involving a small number of iso-
lated, pure enzymes, which at that time
were rather simple and small. As more
complex genes have been analyzed and
expressed over time, it has becomeCell 146, Secommon knowledge that most complex
proteins are notoriously difficult to refold
at concentrations present in cells and at
the bulk concentration of protein that
prevails in cells. Indeed, many proteins
even fold poorly when expressed inside
cells from distant species.
Molecular chaperones provide the solu-
tion to this paradox. In many cases, chap-
erones, such as the Hsp70 chaperone
system, stabilize aggregation-prone (i.e.,
hydrophobic) intermediates. In more diffi-
cult cases, tube-like chaperones, such as
the GroEL/Hsp60 chaperone system, fun-
nel the polypeptide into the protected
internal space of giant ring-based struc-
tures. These two strategies represent the
basic principles that permit proteins to
fold in the cell, and the establishment of
the mechanisms and pathways involved
represents, inour time,anadvancecompa-
rable to that made by Anfinsen in his time.
Indeed, these advances are strictly com-
plementary.Anfinsen’s fundamental chem-
ical conclusion—that a protein’s three-
dimensional shape is determined solely by
its intrinsic chemical composition—is in
no way challenged by Hartl’s and Hor-
wich’s singular advance in cell biology. To
the contrary, molecular chaperones asso-
ciate with their substrates only during the
folding process, and thus they are purely
facilitators that enable a gene product to
efficiently achieve its final folded state
dictated solely by its intrinsic chemistry.
Landmark Papers Set the Stage
Over the past 40 years, many investiga-
tors have identified and characterizedptember 16, 2011 ª2011 Elsevier Inc. 851
Figure 1. Chaperone Pathway for the Folding in the E. coli Cytosol
The Hsp70 chaperones DnaK/DnaJ stabilize the newly synthesized protein in
a nonaggregated, folding-competent state. Transferring the protein into the
central cavity of the Hsp60 chaperone GroEL requires the nucleotide
exchange factor GrpE. GroES binds to GroEL in an ATP-dependent reaction
and displaces the unfolded protein into an enclosed folding cage. The protein
is allowed to fold inside the cage for 10 s, the time needed for GroEL to
complete one round of ATP hydrolysis (of 7 ATPs). Binding of ATP to the
opposite ring of GroEL induces an allosteric change that triggers the opening
of the folding chamber. Folded protein is released, whereas incompletely
folded protein re-binds to GroEL for another round of attempted folding in the
GroEL-GroES cage.individual components of
what we now recognize as
the core chaperone protein
machinery, including phage
assembly factors and pro-
teins upregulated by stress.
And, by the late 1980s, all
the proteins central for protein
folding were virtually known
in both structural and broad
phenotypic terms. In par-
ticular, John Ellis, Costa
Georgopoulos, and George
Lorimer deserve special re-
cognition for their genetic
and biochemical description
of the ‘‘protein-folding cata-
lysts.’’ Georgopoulos was the
first to define the genes for all
the major folding catalysts.
Hiswork asa graduate student
in the early 1970s and then
later as a postdoctoral fellow
led to the mapping of the
E. coli genes GroEL, GroES,
DnaK, DnaJ, and GrpE.
These genes all emerged
from genetic screens for
mutants that affect l phage
assembly and, in the case ofthe latter three genes, play a role in phage
and chromosome replication (Georgo-
poulos and Herskowitz, 1971).
In an entirely independent develop-
ment, in 1980 Ellis discovered the first
molecular chaperone (Barraclough and
Ellis, 1980). He found that unassembled
subunits of the Rubisco enzyme complex
in chloroplasts were associated with ano-
ther protein that turned out to be a chap-
erone. In 1988, Ellis and Georgopoulos
discovered that this chaperone is related
to the GroEL molecule involved in phage
assembly (Hemmingsen et al., 1988).
Ellis coined the term ‘‘chaperonin’’ for
the GroE-type folding catalysts that are
required to assist a variety of cellular pro-
cesses within organelles and in the cyto-
plasm of all types of cells. The following
year and in subsequent detailed enzymo-
logic studies, George Lorimer reconsti-
tuted the assembly of Rubisco subunits
with isolated bacterial chaperonins (Go-
loubinoff et al., 1989).
These foundational studies beautifully
set the stage for Hartl’s and Horwich’s
two landmark papers in 1989. In a key
genetic and biochemical experiment,852 Cell 146, September 16, 2011 ª2011 ElsHartl and Horwich isolated and char-
acterized mutations in mitochondrial
chaperone Hsp60/GroEL. Surprisingly,
mitochondrial proteins were synthesized
and imported successfully, but they failed
to fold. This was the first proof that protein
folding required molecular assistance by
binding proteins (‘‘chaperones’’) in the
living cell (Cheng et al., 1989). The same
team published a second landmark paper
(Ostermann et al., 1989) showing that
mitochondrial Hsp60 from mitochondria
assists the folding ofmonomeric polypep-
tide chains and requires ATP binding and
hydrolysis to do so. This work focused on
the folding of dihydrofolate reductase
(DHFR) when it’s imported into isolated
mitochondria, and it established the prin-
ciple of assisted folding in the cell for sin-
gle polypeptide chains, even those that
can fold spontaneously and efficiently as
pure proteins. This marked a radical de-
parture from the earlier view that protein
folding in the cell can be a spontaneous
process. It is on the basis of these papers
and their future seminal contributions in
establishing the key concepts and molec-
ular mechanisms in cellular protein foldingevier Inc.that Horwich and Hartl stand
out (Figure 1).
It is noteworthy that this
remarkable set of experi-
ments was possible only
because of previous mecha-
nistic insights into how pro-
teins encoded in the nucleus
are imported into mitochon-
dria. These insights emerged
mainly from the laboratories
of Walter Neupert and Gott-
fried Schatz in the previous
decade. Not only was Hartl a
prote´ge´ of Neupert, but
much of his early work on
the Hsp60 chaperones was
carried out directly in Neu-
pert’s laboratory, as reflected
in Neupert’s coauthorship of
the landmark papers. Schatz
and collaborators introduced
the background methods in-
volving DHFR translocation
and folding.
Hsp70s and Folding
in the Cytoplasm
The Hsp70 protein family
provides a second system ofmolecular chaperones. These proteins
are a family of monomeric ATPases,
with Georgopoulos’ bacterial DnaK (an
Hsp70) and its cofactors DnaJ and GrpE
as the prototype of these chaperones. In
all likelihood, the Hsp70 chaperones
supply the most general mechanism of
facilitated protein folding, as the GroEL
system is required for only a small fraction
of the cell’s proteins (Houry et al., 1999).
Key experiments in the laboratories of
Hugh Pelham and Elizabeth Craig first
associated the Hsp70 proteins with pro-
tein folding in the cytoplasm and in quality
control inspection in the secretory path-
way. The DnaK proteins are related to
a family of heat-induced proteins, called
the Hsp70s, which were first described
as heat shock proteins in Drosophila.
Rothman and colleagues discovered that
the Hsp70s bind and hydrolyze ATP
(Chappell et al., 1986). With this in mind,
Pelham was the first to speculate that
Hsp70s promote proper folding or reas-
sembly of proteins by using cycles of
ATP hydrolysis to bind and release ag-
gregated, denatured proteins (Pelham,
1986). Pelham was also the first to
demonstrate that BiP, an Hsp70 ATPase
in the endoplasmic reticulum lumen, was
associated with the assembly of secretory
proteins that fold in the ER (Munro and
Pelham, 1986), implicating Hsp70s in the
folding process. The core biochemical
mechanism—binding and release of ex-
posed hydrophobic segments—was es-
tablished by Rothman and colleagues
(Flynn et al., 1989). Elizabeth Craig devel-
oped a yeast genetic approach to dis-
cover the roles of the cytoplasmic Hsp70s
in maintaining the unfolded state that
favors protein translocation (Deshaies
et al., 1988).
Hartl and Horwich Hook Up
the Pathway
As important as these early discoveries
were in the developing the story of in vivo
protein folding, the experiments of Hartl
and Horwich from 1987 to 1997 created
a coherent picture of the physiologic and
biophysical processes that cells use to
fold proteins. In an extraordinary body of
work between 1991 and 1994, Hartl
defined, resolved, and reconstituted the
complete pathway by which molecular
chaperones cooperate to fold proteins.
In a brilliant series of articles published
in the journal Nature, he linked together
the entire pathway, establishing how the
folding peptide chain is recognized co-
translationally by Hsp70, preventing pre-
mature misfolding (the negative role)
(Langer et al., 1992a; Frydman et al.,
1994), and then transferred sequentially
from Hsp70 to Hsp60/GroEL, which pro-
motes folding (the positive role). He also
then placed in this context many other
(‘‘cochaperone’’) proteins that act as
regulators of the steps in this pathway
(DnaJ, GrpE, GroES).
For most proteins, Hsp70 is essentially
sufficient. The Hsp70 loads onto the
newly synthesized polypeptide chain as
it emerges from the ribosome and stays
on long enough to allow entire folding
domains to be manufactured, thereby
preventing aggregation. It further imparts
energy to the polypeptide as it releases
it, giving folding reactions an extra kick.
When this does not suffice, the chain
(with Hsp70 re-bound to it) is transferred
to the chamber of a GroEL chaperonin
to do the heavy lifting.
By this time, both GroEL (Hendrix,
1979) and proteosomes (Dahlmannet al., 1986) were well known to be cy-
lindrical particles based on oligomeric
ring-forming subunits. This of course
gave rise to speculation that the cavities
may have functional significance. But the
cylindrical shape of the particle did not
intrinsically require that folding (or degra-
dation) occur within the particle, as a
cavity is a structural consequence of any
ring-based oligomer. Direct evidence for
this hypothesis came first for protein
folding inside GroEL in 1992 (and then 3
years later for protein degradation inside
proteosomes in 1995).
Electron microscopy images of GroEL,
taken by Hartl and Baumeister (Langer
et al., 1992b), offered the first indication
that folding occurs within the GroEL
cavity, and this hypothesis was confirmed
in 1993 by Horwich (Braig et al., 1993).
Hartl proposed that the chain folds in
the internal microenvironment provided
by the cavity of Hsp60/GroEL and its lid-
shaped cofactor GroES (Martin et al.,
1993). In essence, a series of ATP-driven
conformational steps change the shape
of the wall of the chamber and ‘‘cock
and load’’ the two symmetrical half
chambers in this molecule. In other
words, ATP binding and hydrolysis drive
conformational changes that open the
chamber to accept an unfolded domain
and then closes the chamber to reinforce
the folding event. Although at first contro-
versial, this beautiful mechanism is now
well accepted and thoroughly confirmed
by X-ray crystal structures of the Hsp60/
GroEL and related proteins.
In 1994, together with Paul Sigler, Hor-
wich solved the X-ray crystal structure
of GroEL, which was one of the largest
protein complexes crystallized at the
time (Braig et al., 1994). An elegant muta-
tional analysis then confirmed, on a struc-
tural basis, that an unfolded protein binds
in the center of the hollow cylindrical
GroEL complex by hydrophobic binding
regions on the apical GroEL domains
facing the central cavity (Fenton et al.,
1994). The ATP-binding sites were also
observed as pockets in the equatorial
domain of each subunit.
More details followed in 1997, when
Horwich and Sigler solved the crystal
structure of the GroEL-GroES complex
(Xu et al., 1997). The structure confirmed
that the inner cavity of GroEL undergoes
a massive conformational change uponCell 146, SeGroES binding. This change results in
the burial of the hydrophobic regions
and formation of a large hydrophilic
chamber in which proteins up to about
60 kDa in size are free to fold. This struc-
ture also identified the mechanism of
ATP hydrolysis, allowing the Horwich
laboratory to work out the nucleotide
reaction cycle (Rye et al., 1997).Perspective
Our current understanding of protein-
folding mechanisms is rather precise.
However, it has not yet revealed how to
control this process when it goes awry
in diseases of protein folding, such as
Alzheimer’s and Huntington’s diseases.
A new field of ‘‘proteostasis’’ seeks to
understand the balance of protein folding,
misfolding, and proteolysis that governs
normal and abnormal cell physiology.
Drugs that target the folding process
and that stabilize a proper folded state
for misfolded proteins, such as mutant
forms of CFTR (Cystic Fibrosis Trans-
membrane Conductance) in cystic fi-
brosis, show promise in the treatment of
a variety of genetic diseases. If we are
able to harness our understanding of
protein chaperones in the treatment of
diseases of protein folding, it will be
because of the pioneering efforts of Hartl,
Horwich, and others who elevated the
field to its current level of molecular
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